BNP Paribas Arbitrage SA Has $41,000 Position in OptiNose Inc (NASDAQ:OPTN)

BNP Paribas Arbitrage SA lifted its holdings in OptiNose Inc (NASDAQ:OPTN) by 1,569.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,006 shares of the company’s stock after purchasing an additional 3,766 shares during the period. BNP Paribas Arbitrage SA’s holdings in OptiNose were worth $41,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of OptiNose in the 4th quarter valued at $45,000. Stifel Financial Corp acquired a new stake in shares of OptiNose in the 4th quarter valued at $63,000. Two Sigma Advisers LP acquired a new stake in shares of OptiNose in the 4th quarter valued at $135,000. Rhumbline Advisers lifted its stake in shares of OptiNose by 58.5% in the 4th quarter. Rhumbline Advisers now owns 23,709 shares of the company’s stock valued at $147,000 after purchasing an additional 8,748 shares during the last quarter. Finally, Teachers Advisors LLC lifted its stake in shares of OptiNose by 31.9% in the 3rd quarter. Teachers Advisors LLC now owns 31,601 shares of the company’s stock valued at $393,000 after purchasing an additional 7,641 shares during the last quarter. 63.68% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of OptiNose from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 target price on shares of OptiNose in a report on Thursday, May 9th. Piper Jaffray Companies set a $29.00 target price on shares of OptiNose and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Finally, Royal Bank of Canada dropped their target price on shares of OptiNose to $25.00 and set an “outperform” rating on the stock in a report on Thursday, March 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $27.80.

Shares of OPTN opened at $6.50 on Wednesday. The firm has a market capitalization of $264.09 million, a P/E ratio of -2.43 and a beta of 1.09. OptiNose Inc has a one year low of $5.66 and a one year high of $30.00. The company has a current ratio of 6.95, a quick ratio of 6.74 and a debt-to-equity ratio of 0.79.

OptiNose (NASDAQ:OPTN) last announced its earnings results on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.01. The firm had revenue of $4.48 million for the quarter, compared to the consensus estimate of $4.35 million. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%. On average, research analysts expect that OptiNose Inc will post -2.91 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2019/06/12/bnp-paribas-arbitrage-sa-has-41000-position-in-optinose-inc-nasdaqoptn.html.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

See Also: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).

Institutional Ownership by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.